drugset / Trial / NCT04279197
Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu
Phase 2
Completed
142 enrolled
ShuGuang Hospital
Huangshi Hospital of Traditional Chinese Medicine · collabHubei Hospital of Traditional Chinese Medicine · collabJingmen No.1 People's Hospital · collabWuhan No.1 Hospital · collabWuhan Third Hospital · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
According to previous studies, viral pneumonia can develop into pulmonary fibrosis, which can affect patients'lung function and even life health.This study aims to observe the efficacy and safety of Fuzheng Huayu Tablets in the treatment of pulmonary fibrosis after COVID-19.
Timeline
- Start
- 2020-04-23
- Primary completion
- 2021-03-24
- Completion
- 2021-03-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fuzheng Huayu tablet | Traditional medicine (herbal / TCM) | 1.6 g | Oral |
| Background | Vitamin C | Other / unclassified | 0.2 g | Oral |